Talha Badar: Deep Dive on the Recent Paper in NEJM Evidence on Randomized Trial IDAC vs HDAC Consolidation in AML
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence
Deep dive on the recent paper published in NEJM Evidence, randomized trial IDAC vs HDAC consolidation in AML (18-60 yrs).
Trial excluded CBF, Ph+ or MPN->AML
Primary endpoint: Overall survival
Secondary endpoint: induction failure, early death, rate of alloHCT in CR1
5 years, OS 59.3% in the IDAC vs 57.5% in the HDAC (HR, 0.96; 95% CI, 0.80 to 1.15; P=0.0042) (Image 2)
Outcomes were comparable across all risk groups (image 3).”
Title: Intermediate-Dose Cytarabine as Postinduction AML Therapy
Authors: Mathilde Hunault, Cécile Pautas, Sarah Bertoli, Pierre-Yves Dumas, Emmanuel Raffoux, Marie-Anne Hospital, Tony Marchand, Maël Heiblig, Sylvain Chantepie, Martin Carré, Pierre Peterlin, Maria-Pilar Gallego-Hernanz, Emilie Lemasle, Romain Guièze, Célestine Simand, Pascal Turlure, Anne Huynh, Thibaut Leguay, Raynier Devillier, Stéphanie Nguyen Quoc, Nicolas Duployez, Isabelle Luquet, Dominique Penther, Karine Celli-Lebras, Ariane Mineur, Nicole Raus, Claude Gardin, Gérard Socié, Jean-Yves Cahn, Norbert Ifrah, Norbert Vey, Régis Peffault de Latour, Eric Delabesse, Claude Preudhomme, Jean-François Hamel, Arnaud Pigneux, Christian Récher, Hervé Dombret
More posts featuring Talha Badar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023